Robert Figlin, MD, FACP

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, talks about the increasingly complicated treatment paradigm for renal cell carcinoma (RCC).

Figlin says drugs like lenvatinib, everolimus, and cabozantinib have emerged in recent years as possible first-line therapies for RCC. He references a recent study published by The New England Journal of Medicine, where patients with advanced RCC had an improved overall survival rate of 5.4 months while on nivolumab versus everolimus.

Videos

Figlin says drugs like lenvatinib, everolimus, and cabozantinib have emerged in recent years as possible first-line therapies for RCC.

Dr. Robert Figlin on the Increasingly Complicated Treatment Paradigm for Renal Cell Carcinoma

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, talks about how TKI therapies, currently in the second-line setting, could function as first-line treatment or in the adjuvant setting.

Figlin says checkpoint inhibitors and next generation single-agent or combination TKIs may be the future of treatment. He adds that while currently sequences of drugs have prolonged survival for kidney cancer patients, it still means patients are receiving drugs for an elongated period of time. Figlin says that he hopes upcoming novel approaches to treating kidney cancer could mean better treatment for patients with less toxicities.

, patients with advanced renal cell carcinoma had an improved overall survival rate of 5.4 months while on nivolumab (Opdivo) versus everolimus (Afinitor).

Dr. Robert Figlin talks about how TKI therapies, currently in the second-line setting, could function as first-line treatment or in the adjuvant setting.

Dr. Robert Figlin on the Future of Treatment for Patients With RCC

Robert Figlin, MD, FACP, professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology Oncology, Cedars-Sinai Medical Center, discusses results from a single-arm phase II trial of the autologous dendritic cell immunotherapy AGS-003 plus standard treatment for patients with newly-diagnosed metastatic renal cell carcinoma (mRCC).

In the trial, patients with mRCC received AGS-003 combined with sunitinib

Updated results show impressive survival findings, including a doubling in progression-free survival and an improvement in overall survival, for patients in the trial compared with a cohort of similar patients that were matched from other trials

In the ongoing phase III ADAPT trial, AGS-003 should be able to demonstrate that a personalized vaccine in combination with sunitinib can enhance outcomes for patients with newly diagnosed mRCC

Robert Figlin, MD, FACP, professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology Oncology, Cedars-Sinai Medical Center, discusses results from a single-arm phase II trial of the autologous dendritic cell immunotherapy AGS-003 plus standard treatment for patients with newly-diagnosed metastatic renal cell carcinoma

Robert Figlin, MD, FACP | Authors

Articles

Dr. Robert Figlin on the Increasingly Complicated Treatment Paradigm for Renal Cell Carcinoma

Dr. Robert Figlin on the Future of Treatment for Patients With RCC

The Efficacy of AGS-003 in mRCC